Adaptimmune Therapeutics plc (ADAP) Social Stream

Adaptimmune Therapeutics plc (ADAP): $1.49

0.02 (+1.36%)

POWR Rating

Component Grades













Add ADAP to Watchlist
Sign Up

Industry: Biotech


of 392

in industry

Adaptimmune Therapeutics PLC (ADAP) Price Targets From Analysts

Use the tables below to see what analysts covering Adaptimmune Therapeutics PLC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-01-14 5 $17 $7 $10.333 $2.13 385.12%
2022-02-23 5 $9 $7 $7.666 $2.13 259.91%
2022-03-14 5 $9 $3 $6.333 $2.13 197.32%

The Trend in the Analyst Price Target

Over the past 130 days, ADAP's average price target has gone down $4.

Over the past 130 days, ADAP's average upside potential has been 172.95%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-11-04 5 17 7 10.333 5.25 96.82%
2021-11-11 5 17 7 10.333 4.70 119.85%
2022-01-14 5 17 7 10.333 3.30 213.12%
2022-02-04 5 9 7 7.666 2.81 172.81%
2022-03-14 5 9 3 6.333 1.82 247.97%

ADAP Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.6 2 0 2 1 1 5

The Trend in the Broker Recommendations

ADAP's average broker recommendation rating improved by 0 over the prior 28 days.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • To contextualize these metrics, consider that out of all US stocks, Adaptimmune Therapeutics PLC's average analyst price target is higher than 19.74% of them.
  • ADAP has a greater upside potential (average analyst target price relative to current price) than 273.24% of all US stocks.
  • In terms of how Adaptimmune Therapeutics PLC fares relative to Healthcare stocks, note that its variance in analysts' estimates is lower than -88.73% of that group.
  • In the context of stocks in the small market cap category, Adaptimmune Therapeutics PLC's number of analysts covering the stock is higher than 191.58% of them.

Stocks similar to Adaptimmune Therapeutics PLC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ACOR, ACHL, and ABOS.

What is the outlook for ADAP? Use POWR Ratings for clearer insight into price direction.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6054 seconds.